

# The EVERLAST-A Study

## Frequently Asked Questions



If you're living with moderate to severe psoriasis but have not found sustained relief from other treatments, you may qualify for the EVERLAST-A Study. The study is evaluating an investigational medication given as a subcutaneous injection (under the skin) to see if it can help relieve the pain, itch, skin irritation, and other symptoms caused by psoriasis.

### 1. What is the purpose of a clinical study?

Clinical studies (also called clinical trials) are used to learn about the safety and effectiveness of investigational medications, medical devices, and medical procedures. Although there are many types of clinical trials, all must conform to strict rules set by local regulatory authorities. These rules help protect the rights and safety of those who volunteer to take part in clinical trials.

### 2. Who is sponsoring the EVERLAST-A Study?

The study is sponsored by Oruka Therapeutics, Inc. (Orukatx.com), a biotechnology company based in California.

### 3. Will I have to pay for anything if I choose to join the EVERLAST-A Study?

No, participants in the study will receive all study-related care at no cost. You will also be compensated for your time and travel to attend study visits.

### 4. Does everyone in the study receive the investigational medication?

There are multiple treatment periods in the study. In the first treatment period (28 weeks), you will have 75% chance of receiving the investigational medication (called ORKA-001), and a 25% chance of receiving a "placebo" (an identical-looking medication, but with no active ingredient). Neither you nor your doctor will know which medication you receive. This is a common technique in clinical studies, as it helps doctors and researchers understand the effects of the investigational medication without bias.

Depending on your results after the first treatment period, you will be re-assigned to receive either ORKA-001 or placebo for an additional 24 weeks; however, if you only received the placebo for the first 28 weeks you will be offered the opportunity to enter a separate study where everyone will receive ORKA-001.

### 5. How long does the EVERLAST-A Study last?

The study lasts up to 106 weeks. After you have completed the study, you may have the opportunity to continue receiving ORKA-001 through another study. Your study team will discuss this with you in further detail.

### 6. What happens during visits?

At every visit, you will be asked about how you are feeling, and your study doctor will examine your skin. At most visits, you will also receive a brief physical exam and will answer questionnaires about your psoriasis symptoms and impact on your quality of life. Throughout the study, depending on the visit, you may also receive other medical exams and will be asked to provide routine blood samples for safety tests.

Before you decide to participate, your study team will provide you with a detailed summary of what will happen at each visit, so that you can make an informed decision about joining the study.

### 7. What if I join the study and decide I do not want to participate anymore?

As with all clinical studies, your participation is completely voluntary and you may leave the study at any time.

### 8. I am interested in possibly moving forward. What is the next step?

Please contact your local study center, and they will work with you to schedule a convenient time for your initial visit.

Thank you for your interest in our study. Please do not hesitate to contact us with any questions!

